One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Fully Automated Coagulometer Market

[ 英語タイトル ] Fully Automated Coagulometer Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0089233
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 117
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Abbott Laboratories
- Erba Group
- F. Hoffmann-La Roche Ltd
- Grifols SA
- HemoSonics LLC
- Haemonetics Corporation
- Horiba
- Instrumentation Laboratory
- Siemens Healthcare
- Sysmex

[Report Description]

The fully automated coagulometer is expected to register rapid growth over the forecast period due to the increasing prevalence of blood-related disorders and developing products.

- Hemophilia is a type of blood disorder which is inherited, it prevents the blood from clotting. According to the World Federation of Haemophilia data, in 2018, around 210,454 people worldwide were diagnosed with hemophilia.
- Moreover, von willebrand disease prevalent cases were accounted to be approximately 78,547 and other bleed disorders were around 48,640. This is expected to boost the demand for fully automated coagulometer. However, the high cost of instruments is expected to obstruct the market growth.

Key Market Trends

Hospital Segment is Expected to Hold a Major Market Share in the Fully Automated Market

- The increasing number of hospitals and it’s developing infrastructure is increasing the demand for fully automated coagulometer devices. According to the American Hospital Association, there are around 5,198 community hospitals in the United States. Furthermore, according to Centers for Medicare & Medicaid Services, the government of United States spent around 4.6% more in 2018 than the preceding year for improving the healthcare infrastructure.
- Also, the increasing adoption of point of care testing by hospitals due to its rapid diagnosis and results, is expected to fuel the demand of fully automated coagulometer.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the market due to the increasing burden of diseases related to blood and cardiovascular. According to the data published by the World Federation of Haemophilia in 2018, around 36,262 people were found to be suffering from some of the other blood disorders in the United States. Furthermore, according to the Center for Disease Control and Prevention, in 2017, around 18.2 million people aged 20 & above suffered from coronary artery disease. Hence, this factor is expected to drive the fully automated coagulometer market growth.

Competitive Landscape

Product launches and strategic alliances by companies are expected to drive the fully automated analyzer market growth. In 2017, Instrument Laboratory acquired Accriva Diagnostics for extending its product line into point of care diagnostics of coagulation and anti-platelet therapy. Furthermore, in 2018, Horiba introduced fully automated coagulometers, Yumizen G800 for laboratories, and Yumizen G1550 for clinical laboratories with a high workload. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are HemoSonics LLC, Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Erba Group, Sysmex, Instrumentation Laboratory, Horiba, Haemonetics Corporation, and Grifols SA.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Blood Related Diseases
4.2.2 Emerging Trends in Product
4.3 Market Restraints
4.3.1 High Cost of Test
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product Type
5.1.1 Coagulation System
5.1.2 Consumables
5.1.3 Accessories
5.2 By End User
5.2.1 Hospitals
5.2.2 Diagnostic Laboratories
5.2.3 Other End Users
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Erba Group
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 Grifols SA
6.1.5 HemoSonics LLC
6.1.6 Haemonetics Corporation
6.1.7 Horiba
6.1.8 Instrumentation Laboratory
6.1.9 Siemens Healthcare
6.1.10 Sysmex




Recommended reports